相关实验视频
Updated: Jul 12, 2026

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
在严重创伤后停止服用华法林的预后影响:基于人口的队列分析
Daniel G Hackam1, Alexander Kopp, Donald A Redelmeier
1Division of Clinical Pharmacology, University of Toronto, Toronto, ON, Canada,
Circulation
|April 27, 2005
概括
在老年患者严重创伤后停止使用华法林并没有增加动脉血栓事件. 然而,停止服用华法林与更高的静脉血栓栓塞的风险有关.
科学领域:
- 老年医学 老年医学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 华法林治疗经常被拒绝给老年患者创伤后由于出血的担忧.
- 在受伤后停止服用华法林对心血管事件的影响尚不清楚.
研究的目的:
- 在老年创伤患者中调查华法林停止和随后的不良心血管事件之间的关联.
主要方法:
- 以人口为基础的回顾性队列研究,使用安大略省,加拿大行政数据库 (1992-2001).
- 包括8450名接受华法林治疗的老年患者 (>65岁),他们经历了严重的创伤.
- 随访患者的平均时间为3.3年,以评估创伤后的结果.
主要成果:
- 22%的患者在创伤后6个月内停止服用华法林.
- 停止服用华法林并没有增加中风或心肌梗塞风险.
- 停止服用华法林与较低的出血风险,但较高的静脉血栓塞栓症风险有关.
结论:
- 在老年创伤患者中停止使用华法林并不会增加动脉血栓事件.
- 在严重创伤后停止服用华法林与静脉血栓栓塞的风险显著增加有关.
相关概念视频
Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Factors Affecting Renal Clearance: Renal Impairment
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Cardiac Output II: Effect of Stroke Volume on Cardiac Output
Cardiac output (CO), the amount of blood the heart pumps per minute, is a parameter in cardiovascular physiology determined by stroke volume and heart rate. Stroke volume, the amount of blood pushed from one of the ventricles per heartbeat, is influenced by preload, afterload, and contractility.
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...